Main Session
Sep
28
PQA 03 - PQA 03: Digital Health Innovation and Informatics, Patient Safety & Quality, and Radiation and Cancer Biology
2429 - Mechanistic Study of PARP Inhibitor Olaparib Combined with Low-Dose Radiotherapy and PD-1 Blockade in Reversing Tumor Immune Desertification and Therapeutic Resistance in Ovarian Cancer
Presenter(s)
Xin Chen, MD, MBBS - Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing